Rabbit Polyclonal CSF3 Antibody

The CSF3 antibody targets granulocyte colony-stimulating factor (G-CSF), a cytokine encoded by the CSF3 gene. G-CSF plays a critical role in regulating neutrophil production, differentiation, and survival by binding to its receptor (G-CSFR) on hematopoietic progenitor cells. It is clinically utilized to treat neutropenia, particularly in chemotherapy patients or those with congenital deficiencies. CSF3 antibodies are primarily employed in research and therapeutic contexts. In research, they help elucidate G-CSF signaling pathways, neutrophil biology, and inflammatory responses. Therapeutically, anti-CSF3 antibodies may be explored to counteract excessive G-CSF activity in autoimmune or inflammatory diseases, though clinical applications remain limited compared to recombinant G-CSF therapies (e.g., filgrastim). Monoclonal CSF3 antibodies are also used in diagnostic assays to quantify G-CSF levels in conditions like sepsis or certain cancers. Challenges include balancing neutrophil modulation without compromising immune defense. Recent studies investigate CSF3 antibodies in oncology to disrupt tumor-associated neutrophil functions or enhance chemotherapy efficacy. However, their dual role in promoting or inhibiting cancer progression requires further mechanistic exploration. Overall, CSF3 antibodies serve as vital tools for understanding and manipulating neutrophil-related physiology and pathology.